- Home
- SSSS vs CSBR Comparison
SSSS vs CSBR Comparison
Compare SSSS & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSSS
- CSBR
- Stock Information
- Founded
- SSSS 2010
- CSBR 1985
- Country
- SSSS United States
- CSBR United States
- Employees
- SSSS N/A
- CSBR N/A
- Industry
- SSSS Finance: Consumer Services
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SSSS Finance
- CSBR Health Care
- Exchange
- SSSS Nasdaq
- CSBR Nasdaq
- Market Cap
- SSSS 138.2M
- CSBR 123.2M
- IPO Year
- SSSS N/A
- CSBR 1986
- Fundamental
- Price
- SSSS $9.98
- CSBR $6.39
- Analyst Decision
- SSSS Strong Buy
- CSBR Strong Buy
- Analyst Count
- SSSS 4
- CSBR 1
- Target Price
- SSSS $9.50
- CSBR $12.00
- AVG Volume (30 Days)
- SSSS 186.1K
- CSBR 40.7K
- Earning Date
- SSSS 11-06-2025
- CSBR 09-15-2025
- Dividend Yield
- SSSS 10.67%
- CSBR N/A
- EPS Growth
- SSSS N/A
- CSBR N/A
- EPS
- SSSS 2.22
- CSBR 0.21
- Revenue
- SSSS $2,784,381.00
- CSBR $56,878,000.00
- Revenue This Year
- SSSS $7,183.09
- CSBR $9.30
- Revenue Next Year
- SSSS N/A
- CSBR $31.17
- P/E Ratio
- SSSS $4.22
- CSBR $29.53
- Revenue Growth
- SSSS N/A
- CSBR 10.11
- 52 Week Low
- SSSS $3.87
- CSBR $3.75
- 52 Week High
- SSSS $9.50
- CSBR $11.99
- Technical
- Relative Strength Index (RSI)
- SSSS 74.65
- CSBR 45.85
- Support Level
- SSSS $8.75
- CSBR $6.27
- Resistance Level
- SSSS $9.40
- CSBR $6.90
- Average True Range (ATR)
- SSSS 0.25
- CSBR 0.28
- MACD
- SSSS 0.05
- CSBR -0.02
- Stochastic Oscillator
- SSSS 99.05
- CSBR 20.65
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.